Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin on Cardiac Remodeling in Post-MI Patients
NCT05335629Completed
- Sponsor
- Ain Shams University
- Start
- Jun 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in myocardial infarction (MI) and ventricular remodeling (VR) (3 arms), sponsored by Ain Shams University. Primary endpoint: Suppression of Tumorigenicity 2 at 4 weeks. Started Jun 2022; status: completed.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)ventricular remodeling (VR)
Beyond the preview
Go deeper on NCT05335629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335629.